Selecta Biosciences Secures $20,000,000 New Funding Round

Feed Type
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=c8179754-be09-4f8c-9de7-e8de9bf28c58
Date
10/15/2014
Company Name
Selecta Biosciences
Mailing Address
480 Arsenal St. Building One Watertown, MA 02472 USA
Company Description
Selecta Biosciences, Inc. is a biopharmaceutical company developing an entirely new class of targeted vaccines that induces an antigen-specific immune activation or antigen-specific immune tolerance for therapeutic and prophylactic applications.
Website
http://www.selectabio.com
Transaction Type
Venture Equity
Transaction Amount
$20,000,000
Transaction Round
Undisclosed
Proceeds Purposes
With strong financial support from both our current and new investors, we are now well positioned to rapidly advance our immune tolerance pipeline, including the lead program SEL-212, the first non-immunogenic treatment for refractory and tophaceous gout.
M&A Terms
Venture Investor